Request to Join
has invited you to join this group
Dr. Joshua Ronen was born and raised in San Jose, CA. He attended Santa Clara University where he majored in Biology with an emphasis in Biomedical Sciences as well as Public Health Sciences. He completed his medical degree (M.D.) at Ross University School of Medicine (RUSM) and his Internal Medicine Residency at Texas Tech University Health Sciences Center School of Medicine at the Permian Basin. Dr. Ronen is presently an attending physician at UCSF Medical Center within the Division of Hospital Medicine - he is serving as a Clinical Hospitalist on the Internal Medicine and Cardiology services. He was also elected to an academic appointment as Clinical Instructor with the UCSF School of Medicine. Additionally, he hopes to continue involvement with the local/regional and national chapters of the American Colleges of Physicians, teaching, and mentorship of residents, medical, and pre-medical students.
Outside of medicine, Dr. Ronen enjoys watching and playing sports, listening to music, cooking, traveling, and spending time with family and friends.
Professional Interests: Hospital Medicine, Critical Care Medicine, Point-of-Care Ultrasound, Graduate Medical Education/Teaching, Program Directroship, Hospital Administration
Dr. Rosenberg completed a fellowship in Hospice and Palliative Medicine at the University of South Florida and a residency in Psychiatry at the University of Maryland.
Dr. DeVincenzo is currently VP of Translational Biology at Enanta Pharmacueticals. He recently completed a 25 year role as a Practicing Pediatric Infectious Diseases Specialist at Le Bonheur Children’s Hospital in Memphis Tennessee and Professor of Pediatrics and Professor of Microbiology, Immunology, and Biochemistry at the University of Tennessee School of Medicine. His research has focused on understanding the pathogenesis of respiratory syncytial virus (RSV) directly in children and using this understanding to develop therapeutic and prevention strategies against this virus. He is the author of over 250 original published abstracts and papers on this subject. Dr. DeVincenzo’s research initially focused on the immunogenetics of RSV disease and the interplay between viral dynamics and RSV disease severity in infants. Subsequently, his research focus shifted to apply this knowledge of RSV dynamics to the development of novel therapeutics for RSV. His development of RNA interference-based therapeutics for RSV has shown recent success. For his groundbreaking proof of concept work applying RNA interference concepts to develop human therapeutics, Dr. DeVincenzo’s study was listed as one of the most influential papers in medicine in 2010 (American Society for Microbiology). From this work, Dr. DeVincenzo set about developing antivirals and vaccines using a variety of approaches for RSV; from conception to proof of concept clinical trials through several academic, foundation, and industry pathways. He and colleagues have demonstrated the first evidence that treating an established RSV infection in humans can lower the viral load and result in reduced disease. He has subsequently extended similar proofs of human antiviral RSV-therapeutic efficacy for four other novel antiviral compounds with different mechanisms of action. He is currently progressing several international RSV antiviral programs into pediatric and adult populations in his new role at Enanta Pharmaceuticals.
Dr. DeVincenzo received his undergraduate degree in biology from Stanford University, and then attended Vanderbilt Medical School where he became interested in pediatric infectious diseases and earned his MD degree. His internship and residency were completed at U.C.L.A Center for Health Sciences. After finishing his pediatrics training, Dr. DeVincenzo studied tropical medicine at Walter Reed and practiced general medicine in Central Africa before starting formal training in Pediatric Infectious Diseases at Boston Children’s Hospital and Harvard Medical School. During this time, he also completed a research fellowship at the Dana Farber Cancer Institute working with his mentor, George Siber, in developing passive antibody approaches for RSV treatment and prevention. Dr. DeVincenzo has conducted numerous clinical and translational trials in children refining the pathogenesis of RSV and defining the role of prevention and therapeutic applications of monoclonal antibodies targeting RSV in infants and the immune suppressed. He ran an active NIH-funded academic laboratory studying RSV and other respiratory viruses for over a decade, and has received numerous honors for his research including honorary induction into Alpha Omega Alpha National Medical Honor Society (2009), the Healthcare Heroes Award for innovation (2008), and the best advance in Therapy and Prevention of a Microbial Disease (ICAAC 2007). Dr. DeVincenzo was also the medical director of the University affiliated Le Bonheur Children’s Hospital Diagnostic Virology Laboratory and the Methodist/Le Bonheur Molecular Diagnostics Laboratory. He is a board certified pediatric infectious disease specialist, has lectured nationally and internationally, and has received awards for clinical teaching of medical students, residents, and fellows.
Vasundhara Singh, MBBS, MD is an Associate Program Director and Internal Medicine Hospitalist at Mount Sinai West and Assistant Professor at the Icahn School of Medicine. Vasundhara’s areas of professional interest include graduate medical education and high value care. Vasundhara can be followed on LinkedIn or contacted via email.